Intellia Therapeutics, a US gene editing company developing CRISPR-based therapies, announced late Thursday its strategic ...

The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% ...

The FDA approved 50 novel drugs in 2024, including 18 biosimilars, with many targeting rare diseases and offering ...

Numab Therapeutics raises $55 million to advance its multi-specific antibody pipeline targeting inflammation and oncology, ...

USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for ...

UCB partners with Ailux Biologics to use XtalPi's AI-driven XtalFold platform for antibody discovery and optimization. The ...

Spanish firm Grifols has submitted a Biologics License Application (BLA) for its new potential fibrinogen treatment to the US ...

Netherlands-based Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic ...

German family-owned pharma major Boehringer Ingelheim has licensed antibody-drug conjugates ADC technology from ...

Shares in French food allergy biotech DBV Technologies (Nasdaq: DBVT) looked set to close more than 10% higher on Thursday.

German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as ...

MitoRx Therapeutics strengthens its leadership with the appointments of Lubor Gaal as chief business officer and Stacey ...